November 2024 – Birmingham – Informed Genomics has been included in the Department for Business and Trade’s (DBT) Genomics Spotlight 2024, which showcases the UK’s expertise in genomics and latest developments that make the UK a hub for genomics business and investment.
Informed Genomics was founded in 2022 and some of the key highlights from the past two years include:
- Launched and upheld ISO 15189 accredited clinical services
- Appointed by NHS England as the only private laboratory to support the delivery of the BRCA gene testing programme for the Jewish community
- Partnered with Bupa as the first UK health insurer to cover GALEAS™ Bladder test
- Launched a service evaluation for GALEAS Bladder with NHS Trusts
- Won awards for delivering innovation in health care
Published today, the DBT has worked closely with the NHS, including NHS England and all three of the devolved nations, to develop this comprehensive guide. It highlights both the export potential of UK companies, as well as the investment potential across the wider NHS infrastructure and research institutes.
Simon Davis, CEO of Informed Genomics, part of the Advanced Genomics group, said: “We are enormously proud of all we have achieved in the last two years. It’s lovely to be acknowledged by the BDT in this way, which is a reminder of the world-leading genomics capabilities we have here in the UK. This is a hugely exciting time for us as a business, as we continue to forge relationships with the NHS and providers in the private sector, as well as the for this dynamic sector in which we operate”.
